-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Nemonoxacin in Diabetic Foot Infection (DFI)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Nemonoxacin in Diabetic Foot Infection (DFI) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Nemonoxacin in Diabetic Foot Infection (DFI) Drug Details: Nemonoxacin (Taigexyn,...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Nemonoxacin in Community Acquired Pneumonia
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Nemonoxacin in Community Acquired Pneumonia report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.Nemonoxacin in Community Acquired Pneumonia Drug Details: Nemonoxacin (Taigexyn, Wingard) is a...
-
Product Insights
Influenza A Virus, H7N9 Subtype Infections Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Influenza A Virus, H7N9 Subtype Infections Pipeline Drugs Market Report Overview Avian influenza A (H7N9) is a subtype of influenza viruses. This infection is seen both in humans and birds. Infection is caused when a person is exposure to infected poultry or contaminated environments. Symptoms include fever, cough that produces sputum, headache, myalgia, and general malaise. Treatment includes antiviral drugs. The Influenza A Virus, H7N9 Subtype Infections pipeline drugs market research report provides comprehensive information on the Influenza A Virus,...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – furaprevir
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry furaprevir Drug Details TG-2349 (furaprevir) is under development for the treatment of chronic hepatitis...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – nemonoxacin
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry nemonoxacin Drug Details Nemonoxacin (Taigexyn) is a non-fluorinated quinolone antibiotic. It is formulated as...
-
Product Insights
Hepatitis B Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
The Hepatitis B virus can cause an acute illness with symptoms that last several weeks, including yellowing of the skin and eyes (jaundice), dark urine, extreme fatigue, nausea, vomiting, and abdominal pain. The Hepatitis B pipeline market research report provides comprehensive information on the therapeutics under development for Hepatitis B, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action of the...
-
Sector Analysis
Methicillin-Resistant Staphylococcus Aureus (MRSA) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape
MRSA spreads through direct contact with another infected person. Most staph infections, including MRSA, initially appear as a bump on the skin that may be red, swollen, painful, warm to the touch, and full of pus or other drainage, and may also be accompanied by a fever. The symptoms of MRSA infections depend strongly on the infection site, the infecting strain, the presence of bacteria virulence factors, the presence of host factors such as comorbidities and immune response, as well...
-
Product Insights
Hepatitis C Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Hepatitis C occurs with multiple symptoms including abdominal pain, fatigue, fever, jaundice, loss of appetite, nausea, and vomiting. The predisposing factors of hepatitis C include dialysis, organ transplant, and blood transfusion. The Hepatitis C pipeline drugs market research report provides an analysis of the Hepatitis C drugs by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The guide also covers the descriptive pharmacological action of the therapeutics, its complete research and development...
-
Product Insights
Influenzavirus B Infections Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Influenza Virus B Infections pipeline market research report provides comprehensive information on the therapeutics under development for Influenza Virus B Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Influenza Virus...
-
Product Insights
Community Acquired Pneumonia Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Community-acquired pneumonia (CAP) is defined as pneumonia acquired outside a hospital or long-term care facility. Symptoms include cough, fever, shaking chills, confusion, headache and loss of appetite. Risk factors include chronic lung disease, cigarette smoking, dementia, stroke, brain injury, heart disease, liver cirrhosis and diabetes mellitus. Treatment includes antibiotics and healthy lifestyle. The Community-acquired Pneumonia Drugs in Development market research report provides an in-depth analysis of the Community-acquired Pneumonia pipeline landscape. The report provides comprehensive information on the therapeutics under...